Neurogene, Inc./$NGNE
1D1W1MYTD1Y5YMAX
Capital at risk
About Neurogene, Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
- Ticker
- $NGNE
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 131
- Headquarters
- New York, United States
- Website
- www.neurogene.com
Neurogene, Inc. Metrics
BasicAdvanced
$710M
-
-$5.04
1.95
-
Price and volume
Market cap
$710M
Beta
1.95
52-week high
$43.66
52-week low
$15.93
Average daily volume
206K
Financial strength
Current ratio
10.645
Quick ratio
10.501
Long term debt to equity
0.024
Total debt to equity
0.038
Interest coverage (TTM)
-40,409.00%
Profitability
EBITDA (TTM)
-117.99
Management effectiveness
Return on assets (TTM)
-27.97%
Return on equity (TTM)
-45.32%
Valuation
Price to book
2.59
Price to tangible book (TTM)
2.59
Price to free cash flow (TTM)
-8.911
Free cash flow yield (TTM)
-11.22%
Free cash flow per share (TTM)
-3.982
Growth
Earnings per share change (TTM)
17.26%
3-year earnings per share growth (CAGR)
-15.36%
Upcoming events
No upcoming events
Neurogene, Inc. News
AllArticlesVideos
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire2 weeks ago
Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates
Business Wire1 month ago
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire2 months ago
Funds containing Neurogene, Inc.
AllUSDGBPEUR
Fund name | Fund size | $NGNE weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.04% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.04% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.